169 related articles for article (PubMed ID: 18231919)
1. High prevalence of human T-lymphotropic virus type I carriers among patients with myelodysplastic syndrome refractory anemia with excess of blasts (RAEB), RAEB in transformation and acute promyelocytic leukemia.
Inoue H; Matsushita K; Arima N; Hamada H; Uozumi K; Ozaki A; Akimoto M; Kawada H; Kukita T; Yoshimitsu M; Matsumoto T; Tei C
Leuk Lymphoma; 2008 Feb; 49(2):315-21. PubMed ID: 18231919
[TBL] [Abstract][Full Text] [Related]
2. Cytogenetic evolution following the transformation of myelodysplastic syndrome to acute myelogenous leukemia: implications on the overlap between the two diseases.
Ghaddar HM; Stass SA; Pierce S; Estey EH
Leukemia; 1994 Oct; 8(10):1649-53. PubMed ID: 7934160
[TBL] [Abstract][Full Text] [Related]
3. Re-evaluation of refractory anemia with excess blasts in transformation.
Ohyashiki K; Nishimaki J; Shoji N; Miyazawa K; Kimura Y; Ohyashiki JH
Leuk Res; 2001 Nov; 25(11):933-9. PubMed ID: 11597728
[TBL] [Abstract][Full Text] [Related]
4. Effect of diagnosis (refractory anemia with excess blasts, refractory anemia with excess blasts in transformation, or acute myeloid leukemia [AML]) on outcome of AML-type chemotherapy.
Estey E; Thall P; Beran M; Kantarjian H; Pierce S; Keating M
Blood; 1997 Oct; 90(8):2969-77. PubMed ID: 9376577
[TBL] [Abstract][Full Text] [Related]
5. Karyotype is prognostically more important than the FAB system's distinction between myelodysplastic syndrome and acute myelogenous leukemia.
Estey EH; Keating MJ; Dixon DO; Trujillo JM; McCredie KB; Freireich EJ
Hematol Pathol; 1987; 1(4):203-8. PubMed ID: 3504436
[TBL] [Abstract][Full Text] [Related]
6. Prognostic value of clonal chromosomal abnormalities in patients with primary myelodysplastic syndromes.
Gyger M; Infante-Rivard C; D'Angelo G; Forest L; Lussier P
Am J Hematol; 1988 May; 28(1):13-20. PubMed ID: 3369432
[TBL] [Abstract][Full Text] [Related]
7. Immunologic characteristics and prognosis of myelodysplastic syndrome new subtype: refractory anemia with excess blasts-II.
Wei J; Zhou XF; Zhao F; Zhou JF; Chen Y
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2009 Feb; 17(1):111-6. PubMed ID: 19236759
[TBL] [Abstract][Full Text] [Related]
8. Clinical aspects of the myelodysplastic syndromes (MDS) with special reference to refractory anemia with excess of blasts (RAEB).
Omine M; Yamauchi H
Nihon Ketsueki Gakkai Zasshi; 1989 Jul; 52(4):800-10. PubMed ID: 2618556
[TBL] [Abstract][Full Text] [Related]
9. [Alteration of methylation status of fragile histidine triad gene promoter in patients with myelodysplastic syndrome].
Yao DM; Qian J; Xu WR; Lin J; Jiang YW; Fei X; Han LX; Wang Y; Cen JN; Chen ZX
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2008 Feb; 25(1):36-9. PubMed ID: 18247301
[TBL] [Abstract][Full Text] [Related]
10. Myelodysplastic syndromes--a population-based study on transformation and survival.
Hörnsten P; Wahlin A; Rudolphi O; Nordenson I
Acta Oncol; 1995; 34(4):473-8. PubMed ID: 7605654
[TBL] [Abstract][Full Text] [Related]
11. Apoptosis, bcl-2 expression and p53 accumulation in myelodysplastic syndrome, myelodysplastic-syndrome-derived acute myelogenous leukemia and de novo acute myelogenous leukemia.
Kurotaki H; Tsushima Y; Nagai K; Yagihashi S
Acta Haematol; 2000; 102(3):115-23. PubMed ID: 10692673
[TBL] [Abstract][Full Text] [Related]
12. Treatment with low-dose cytosine arabinoside followed by administration of macrophage colony-stimulating factor prolongs the survival of patients with RAEB, RAEB-T, or leukemic phase myelodysplastic syndrome: a pilot study.
Fukuhara T; Miyake T; Maekawa I; Kurosawa M; Suzuki S; Noto S; Mori A; Chiba K; Toyoshima T; Hirano T; Morioka M; Tsutsumi Y; Okabe M; Kakinoki Y
Int J Hematol; 2000 Jun; 71(4):366-71. PubMed ID: 10905057
[TBL] [Abstract][Full Text] [Related]
13. [Expression of Fas, FasL and Bcl-2 and apoptosis of bone marrow CD34+ cells in patients with myelodysplastic syndrome].
Zhang Z; Xie J
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2003 Jun; 11(3):274-7. PubMed ID: 12844412
[TBL] [Abstract][Full Text] [Related]
14. Comparison of the distribution and clonal expansion features of the T-cell γδ repertoire in myelodysplastic syndrome-RAEB and RAEB with progression to AML.
Geng S; Weng J; Du X; Lai P; Huang X; Chen S; Yang L; Li Y
DNA Cell Biol; 2012 Oct; 31(10):1563-70. PubMed ID: 22873198
[TBL] [Abstract][Full Text] [Related]
15. De novo acute myeloid leukemia with 20-29% blasts is less aggressive than acute myeloid leukemia with ≥30% blasts in older adults: a Bone Marrow Pathology Group study.
Hasserjian RP; Campigotto F; Klepeis V; Fu B; Wang SA; Bueso-Ramos C; Cascio MJ; Rogers HJ; Hsi ED; Soderquist C; Bagg A; Yan J; Ochs R; Orazi A; Moore F; Mahmoud A; George TI; Foucar K; Odem J; Booth C; Morice W; DeAngelo DJ; Steensma D; Stone RM; Neuberg D; Arber DA
Am J Hematol; 2014 Nov; 89(11):E193-9. PubMed ID: 25042343
[TBL] [Abstract][Full Text] [Related]
16. Hepatitis B and C viruses, human T-cell lymphotropic virus types I and II, and leukemias: a case-control study. The Italian Leukemia Study Group.
Gentile G; Mele A; Monarco B; Vitale A; Pulsoni A; Visani G; Castelli G; Rapicetta M; Verani P; Martino P; Mandelli F
Cancer Epidemiol Biomarkers Prev; 1996 Mar; 5(3):227-30. PubMed ID: 8833624
[TBL] [Abstract][Full Text] [Related]
17. Primary myelodysplastic syndrome: an analysis of 56 patients.
Chen PH; Kuo CY; Huang CH; Shih LY
Changgeng Yi Xue Za Zhi; 1992 Sep; 15(3):121-7. PubMed ID: 1468034
[TBL] [Abstract][Full Text] [Related]
18. Primary myelodysplastic syndrome: clinical spectrum of 53 cases.
Irfan M; Kakepoto GN; Khursheed M
J Pak Med Assoc; 1998 Mar; 48(3):69-73. PubMed ID: 9783031
[TBL] [Abstract][Full Text] [Related]
19. Refractory anemia with excess of blasts in transformation: analysis of reclassification according to the WHO proposals.
Strupp C; Gattermann N; Giagounidis A; Aul C; Hildebrandt B; Haas R; Germing U
Leuk Res; 2003 May; 27(5):397-404. PubMed ID: 12620291
[TBL] [Abstract][Full Text] [Related]
20. High remission rate, short remission duration in patients with refractory anemia with excess blasts (RAEB) in transformation (RAEB-t) given acute myelogenous leukemia (AML)-type chemotherapy in combination with granulocyte-CSF (G-CSF).
Estey EH; Kantarjian HM; O'Brien S; Kornblau S; Andreeff M; Beran M; Pierce S; Keating M
Cytokines Mol Ther; 1995 Mar; 1(1):21-8. PubMed ID: 9384660
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
